Detection of adverse drug reaction (ADR)-related hospital admissions: A pilot study using administrative database for ADR monitoring in Thailand

Siltharm, Chinattaya; Pattanaprateep, Oraluck; Pongcharoensuk, Petcharat; Jeanpeerapong, Napawan; Thavorncharoensap, Montarat

doi:10.29090/psa.2017.03.142

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the characteristics of ADEs in our study differed from those in other countries. For example, in a retrospective study examining ADR-related hospital admissions at a single hospital in Thailand, ‘drug-induced neutropenia’ was the most common ( Siltharm et al, 2017 ). Another study conducted in England, Germany, and the United States revealed that ‘Enterocolitis due to Clostridium difficile ’ was the most frequent type of ADEs ( Stausberg, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

Exploring the prevalence and characteristics of adverse drug events among older adults in South Korea using a national health insurance database

2022

View full text Add to dashboard Cite

Background: Adverse drug events (ADEs) in the elderly frequently occur because of their multiple chronic diseases and complexity of drug therapy. To better understand adverse drug events, the prevalence and characteristics of adverse drug events in elderly South Korean patients were assessed.Methods: The National Health Insurance databases for 2015 and 2016 were used for the analysis. We included patients aged ≥65 years that had at least one claim with the diagnosis codes ‘drug-induced,’ ‘poisoning by drug,’ and ‘vaccine-associated’ each year for the base-case analysis. To minimize the underestimation of adverse drug event prevalence, we also used an extended definition analysis by adding the ‘adverse drug event very likely’ codes. We estimated the prevalence of adverse drug events by sex, age group, and type of insurance and examined the frequent types of adverse drug events in 2015 and 2016.Results: In the base-case analysis, adverse drug event prevalence in individuals aged 65 years and older was 2.75% in 2015 and 2.77% in 2016. With advanced age, the prevalence of adverse drug event tended to increase, peaking in the age group of 75–79 years. In addition, the adverse drug event prevalence was higher in females and Medical Aid enrollees. The most frequently occurring adverse drug event was ‘allergy, unspecified,’ followed by ‘other drug-induced secondary parkinsonism,’ and ‘generalized skin eruption due to drugs and medicaments.’ When we examined the extended definition analysis, the prevalence of adverse drug events was 4.47% in 2015 and 4.52% in 2016, which significantly increased from those estimated in the base-case analysis.Conclusion: Among the older adults, the prevalence of adverse drug event was higher in advanced age, females, and Medical Aid enrollees. In particular, allergy and drug-induced secondary parkinsonism frequently occurred. This study provides evidence that health policies addressing the prevention and management of adverse drug events should be a priority for the most vulnerable elderly patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the prevalence and characteristics of adverse drug events among older adults in South Korea using a national health insurance database

2022

View full text Add to dashboard Cite

show abstract

“…From earlier reviews [17,[23][24][25]27,28], findings have reported the presence of methodological heterogeneity between studies measuring ADR costs in terms of assessing causal relationships between the drug and the resulting morbidity, and how to define ADR. This is similar to our review, where there is also a large heterogeneity between the methods and cost sources used for cost analysis within these studies.…”

Section: Streamlining Adr Costing Methodsmentioning

confidence: 99%

“…However, the current scarcity of evidence, on top of the heterogeneity of findings, makes the interpretation of findings difficult. For instance, between 1998 and 2013, there were at least 14 systematic reviews on the incidence and risk factors of ADRs [6,[17][18][19][20][21][22][23][24][25][26][27][28]. Out of this, only three of them [17,25,27] looked into ADR costs while only one [29] explored the potential effect of methodological approaches to cost estimations.…”

Section: Introductionmentioning

confidence: 99%

“…For instance, between 1998 and 2013, there were at least 14 systematic reviews on the incidence and risk factors of ADRs [6,[17][18][19][20][21][22][23][24][25][26][27][28]. Out of this, only three of them [17,25,27] looked into ADR costs while only one [29] explored the potential effect of methodological approaches to cost estimations. Furthermore, the lack of consistent cost data and unascertained methodological influences also limit the ability to evaluate cost-effectiveness strategies such as pharmacovigilance programs, medication reviews, and patient education campaigns.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost Estimations of Managing Adverse Drug Reactions in Hospitalized Patients: A Systematic Review of Study Methods and Their Influences

Abu

Shafie

Chandriah

2023

Pharmacoepidemiology

View full text Add to dashboard Cite

This study aimed to systematically review and explore the impact of study methods on the cost of managing adverse drug reactions (ADRs) among hospitalized patients to guide policymakers and researchers. A literature search was conducted in MEDLINE, EMBASE, CINAHL, Cochrane Library, and Google Scholar. The search was restricted to studies from 2000 to 2017. Two authors independently reviewed the studies, assessed their risk of bias, and extracted information for analysis. Data abstraction was based on the study design, ADR reporting, and costing approaches. Of 677 studies identified, 12 were included for analysis. All studies defined ADR according to WHO classifications. The percentage of admission due to ADR ranged from 0.03% to 17.11%. All studies adopted a healthcare provider perspective, using either a micro-costing (n = 7), case-mix group costing (n = 3), or average-per-diem costing (n = 2) approach. The cost per ADR widely fluctuated from USD 65.00 to USD 12,129.90 based on various factors. The micro-costing approach generally had a lower cost compared to other approaches. The cost per ADR in high-income countries was also 10 times higher than in lower- or middle-income countries. This study evidenced that the methodological heterogeneity across studies has resulted in a wide range of cost estimations for ADR management.

show abstract

Detection of adverse drug reaction (ADR)-related hospital admissions: A pilot study using administrative database for ADR monitoring in Thailand

Abstract: This study aims to examine incidence, characteristics, and trend of ADR-related admissions at one tertiary care hospital in Thailand during a five-year period

Cited by 2 publications

References 18 publications

Exploring the prevalence and characteristics of adverse drug events among older adults in South Korea using a national health insurance database

Exploring the prevalence and characteristics of adverse drug events among older adults in South Korea using a national health insurance database

Cost Estimations of Managing Adverse Drug Reactions in Hospitalized Patients: A Systematic Review of Study Methods and Their Influences

Contact Info

Product

Resources

About